Latest Administration News

Island Pharmaceuticals has expanded its partnership with USAMRIID to conduct a pivotal Galidesivir dose optimisation study against Marburg virus, targeting topline results in the second half of 2026.

Urbanise.com Limited is poised to transform the Australian strata sector with a staged pilot release of its enhanced Strata platform, integrating NAB banking services and launching a branded owners portal from July 2026.

Imugene’s off-the-shelf CAR T therapy azer-cel has won FDA Fast Track Designation for relapsed or refractory CLL/SLL and MZL, backed by compelling Phase 1b response rates.

OncoSil Medical has cleared a major regulatory hurdle as its Humanitarian Device Exemption application nears FDA approval, while its TRIPP-FFX trial shows promising results combining OncoSil with standard chemotherapy for pancreatic cancer.

Alterity Therapeutics has clinched FDA agreement on the pivotal Phase 3 trial design for ATH434, targeting Multiple System Atrophy, with the trial set to begin by the end of 2026.

Perpetual Limited is set to acquire a majority stake in loan servicing technology firm Interfi Systems, enhancing its Corporate Trust division’s digital capabilities while targeting a 15% reduction in gross debt by June 2026.

Urbanise is set to launch a unified strata payments platform integrated with NAB banking, promising streamlined workflows and a branded owners portal from July 2026.

Opthea Limited resumes ASX trading as it pivots to develop OPT-302 for lymphangioleiomyomatosis, outlining a disciplined 18-month staged clinical program backed by A$31.2 million in cash.

AFC Group Holdings reported a sharp 78% drop in revenue to NZ$161,000 and a net loss of NZ$818,000 for FY2026, but secured shareholder backing and plans to expand its wine portfolio and distribution reach.

Dome Gold Mines (ASX:DME) is raising up to AUD 2 million through unsecured convertible notes to fast-track its Sigatoka feasibility study, mining lease application, and copper-gold exploration amid rising metal prices.

Imagion Biosystems has secured FDA clearance to proceed with its Phase 1b/2 trial of the MagSense® HER2 Imaging Agent, targeting improved detection of HER2+ breast cancer. Patient recruitment is expected to start in Q3 2026, marking a crucial step toward commercialisation.

Entropy Neurodynamics has successfully dosed all six participants in the first cohort of its Phase 2 trial for TRP-8803, an intravenous psilocin therapy targeting Binge Eating Disorder. The study demonstrated controlled psychedelic responses, setting the stage for a Data and Safety Monitoring Board review and topline results expected in July 2026.